Blood · 2014 · 126 citations · 17 references
Life SciencesGeneticsMolecular GeneticsCancer GeneticsCytogeneticsMolecular OncologyChromosomal AberrationsChromosomal AbnormalitiesChromosomal TranslocationsClinical CytogeneticsMolecular CytogeneticsOncogene MutationsAcute Myeloid Leukemia BiologyAcute Promyelocytic LeukemiaCytogenetics In Hematologic DiseaseLeukemia CytogeneticsRunx Family OncogenesRunx1 In Hematopoietic DevelopmentTranslocation-associated Leukemias
Acute myeloid leukemia (AML) with t(8;21) (q22;q22) is considered to have favorable risk; however, nearly half of t(8;21) patients are not cured, and recent studies have highlighted remarkable genetic heterogeneity in this subset of AML. Here we identify somatic mutations in additional sex combs-like 2 (ASXL2) in 22.7% (25/110) of patients with t(8;21), but not in patients with inv(16)/t(16;16) (0/60) or RUNX1-mutated AML (0/26). ASXL2 mutations were similarly frequent in adults and children t(8;21) and were mutually exclusive with ASXL1 mutations. Although overall survival was similar between ASXL1 and ASXL2 mutant t(8;21) AML patients and their wild-type counterparts, patients with ASXL1 or ASXL2 mutations had a cumulative incidence of relapse of 54.6% and 36.0%, respectively, compared with 25% in ASXL1/2 wild-type counterparts (P = .226). These results identify a high-frequency mutation in t(8;21) AML and identify the need for future studies to investigate the clinical and biological relevance of ASXL2 mutations in this unique subset of AML.
17
<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia
Timothy J. Ley, Li Ding, Matthew J. Walter et al. · New England Journal of Medicine · 2010 · 2K citations · Full text
David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text
Life Sciences, Hematology, Oncology +16